Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2012

View Archived Issues

Novel antimitotic compounds created in joint venture

ProINS-Tf fusion protein displays hypoglycemic activity

Vivalis discloses novel agents for hepatitis C virus infection

An anti-M1 prime monoclonal antibody shows promising results in allergic rhinitis and asthma

Researchers at the University of California divulge new SEH inhibitors

Novel ROCK-II inhibitors prepared at Boehringer Ingelheim

New proton pump inhibitor shows promise in Japanese patients with GERD

Combination of Ad-rhE and chemotherapy proves beneficial in cancer patients

Oncolytic viral therapy shows potential as treatment for superficial tumors

Enrollment completed in phase II study of NP-2 enkephalin in cancer pain

Phase I trial opens enrollment for GeoVax Labs' HIV vaccine

AVEO begins phase I AV-203 study in advanced solid tumors

Novel pegylated interferon alpha variant conjugates generated in China

Phase III CompleoTRT trial nearing full enrollment

Seattle Genetics' Adcetris NDS accepted for review by Health Canada

Pfizer presents new ACC inhibitors

Label update approved for Tysabri to include anti-JC virus antibody status

Korean scientists present novel HIF-1 inhibitors

Preliminary phase I results show IW-001 to be well tolerated

XDx and LabCorp enter collaboration for SLE diagnostic

EMA acceptance of Takeda's alogliptin MAA triggers milestone payment for Furiex

FDA advisory committee votes against Xarelto use in new ACS indication

Preliminary phase IIb results display encouraging responses to Celldex' CDX-011

EMA validates Gilead's MAA for boosting agent cobicistat

MediciNova reports preliminary results for MN-221 in asthma exacerbations

Immune Pharmaceuticals and Yeda partner to develop anticancer therapies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...